Fennec Pharmaceuticals (FENC) Earnings Analysis
Fennec Pharmaceuticals (FENC) next reports earnings on 2026-08-13, consensus EPS 0.01 USD. Last quarter (2026-05-14) it beat with EPS 0.01 USD vs -0.02 USD est (+150%). It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E -33.60.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does FENC next report earnings?
| Next earnings date | 2026-08-13 |
|---|---|
| Consensus EPS estimate | 0.01 USD |
| Revenue estimate | 0.02B |
FENC earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-14 | 0.01 USD | -0.02 USD | +150% | Beat |
| 2026-03-24 | -0.11 USD | 0.03 USD | -466.7% | Miss |
| 2025-11-13 | -0.02 USD | -0.08 USD | +75% | Beat |
| 2025-08-14 | -0.11 USD | -0.06 USD | -83.3% | Miss |
| 2025-03-10 | -0.06 USD | 0.56 USD | -110.7% | Miss |
| 2024-11-07 | -0.21 USD | -0.13 USD | -61.5% | Miss |
Beat rate: 2/6 (33%) over reported quarters with consensus data.
FENC valuation and analyst view
| Trailing P/E | -33.60 |
|---|---|
| Trailing EPS | -0.24394 USD |
| Price / book | 9.41 |
| Dividend yield | 0.00% |
| Market cap | 0.29B |
| Analyst consensus | Buy (7 buy / 0 hold / 0 sell) |
| Avg price target | 16 USD |
Related research pages
Frequently asked questions
When is Fennec Pharmaceuticals (FENC)'s next earnings date?
Fennec Pharmaceuticals is next scheduled to report on 2026-08-13, with a consensus EPS estimate of 0.01 USD and revenue estimate of 0.02B.
Did FENC beat earnings last quarter?
In its 2026-05-14 report, FENC posted EPS of 0.01 USD versus a -0.02 USD estimate — a beat of 150%.
What is FENC's earnings track record?
Over the last 6 reported quarters with consensus data, FENC beat estimates 2 times (33%).
What is FENC's current P/E ratio and EPS?
FENC trades at a trailing P/E of -33.60 on trailing EPS of -0.24394221808014913 USD.
What do analysts rate FENC?
Analyst consensus is "Buy" across 7 ratings (0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 16 USD.